BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 28243993)

  • 1. What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?
    Voorhies BN; Stephens DM
    Curr Treat Options Oncol; 2017 Feb; 18(2):12. PubMed ID: 28243993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
    Robak T; Burger JA; Tedeschi A; Barr PM; Owen C; Bairey O; Hillmen P; Simpson D; Grosicki S; Devereux S; McCarthy H; Coutre SE; Quach H; Gaidano G; Maslyak Z; Stevens DA; Moreno C; Gill DS; Flinn IW; Gribben JG; Mokatrin A; Cheng M; Styles L; James DF; Kipps TJ; Ghia P
    Am J Hematol; 2018 Nov; 93(11):1402-1410. PubMed ID: 30129285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Treatment of Chronic Lymphocytic Leukemia.
    Jamroziak K; Puła B; Walewski J
    Curr Treat Options Oncol; 2017 Jan; 18(1):5. PubMed ID: 28185174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
    Ladyzynski P; Molik M; Foltynski P
    Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
    Cramer P; Langerbeins P; Eichhorst B; Hallek M
    Eur J Haematol; 2016 Jan; 96(1):9-18. PubMed ID: 26332019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
    Jain N; O'Brien S
    Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
    Owen C; Bence-Bruckler I; Chamakhi I; Toze C; Assaily W; Christofides A; Robinson S
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):303-13. PubMed ID: 25937158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial therapy of chronic lymphocytic leukemia.
    Eichhorst B; Cramer P; Hallek M
    Semin Oncol; 2016 Apr; 43(2):241-50. PubMed ID: 27040702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?
    Milunović V; Mišura Jakobac K; Mandac Rogulj I; Martinović M; Radić-Krišto D; Ostojić Kolonić S
    Expert Rev Hematol; 2020 Jul; 13(7):771-779. PubMed ID: 32579408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial treatment of CLL: integrating biology and functional status.
    Jain N; O'Brien S
    Blood; 2015 Jul; 126(4):463-70. PubMed ID: 26065656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
    Wendtner CM; Gregor M
    Leuk Lymphoma; 2018 Feb; 59(2):300-310. PubMed ID: 28565930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
    Hallek M
    Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia.
    Innocenti I; Autore F; Pasquale R; Morelli F; Efremov DG; Laurenti L
    Expert Rev Hematol; 2017 Dec; 10(12):1069-1076. PubMed ID: 29082795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
    Byrd JC; Jones JJ; Woyach JA; Johnson AJ; Flynn JM
    J Clin Oncol; 2014 Sep; 32(27):3039-47. PubMed ID: 25049322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chronic lymphocytic leukemia: current standards and novel approaches].
    Tausch E; Stilgenbauer S
    Internist (Berl); 2014 Dec; 55(12):1400, 1402-4, 1406-9. PubMed ID: 25392275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic markers and standard management of chronic lymphocytic leukemia.
    Stilgenbauer S
    Hematology Am Soc Hematol Educ Program; 2015; 2015():368-77. PubMed ID: 26637745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.
    Owen C; Assouline S; Kuruvilla J; Uchida C; Bellingham C; Sehn L
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):627-634.e5. PubMed ID: 26416145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.
    Jacobs RW; Awan FT; Leslie LA; Usmani SZ; Ghosh N
    Expert Rev Hematol; 2016 Dec; 9(12):1177-1187. PubMed ID: 27791448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.